Leukocyte disorder

This phase 1 trial is testing a new gene therapy called UB-VV500 for people with multiple myeloma that has returned or stopped responding to treatment. The therapy works by giving the body genetic instructions to produce its own CAR T cells that target two proteins on myeloma cel…

This trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…

This phase 1 trial is testing an experimental therapy called CD19/CD20 dual-target in vivo CAR-T for people with relapsed or refractory B-cell malignancies—blood cancers that have not responded to standard treatments. The approach uses a lentiviral product to engineer a patient's…

This trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…

This trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T c…

This early-stage trial is investigating whether a new type of CAR T-cell therapy, which targets a protein called BAFFR on cancer cells, can safely and effectively treat adults with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma that has returned or not respo…

This phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…

This Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…

This early-stage trial is testing an experimental therapy called KIV-318 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. KIV-318 is a type of CAR-T cell therapy that reprograms a patient's own immune cells to recognize …

This study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…

This phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …

This Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…

This early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.

This phase 3 trial is testing whether a radioactive drug called iopofosine I 131 can keep Waldenstrom macroglobulinemia (a rare blood cancer) from getting worse for longer than the standard combination of rituximab, cyclophosphamide, and dexamethasone (R-CD). The study enrolls ab…

This phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (DA-EPOCH-R) helps people with high-risk Burkitt lymphoma. About 43 adults will receive the combination. The study will check how many complete at least three cycles of treatment and track overa…

This phase II trial is testing whether a new investigational drug called IBI3003, when combined with an existing anti-CD38 antibody (daratumumab), can improve outcomes for people with multiple myeloma. The study includes patients with relapsed or refractory disease, as well as ne…

This trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…

This trial is testing whether adding an immunotherapy drug called penpulimab to a standard chemotherapy regimen can help people with primary central nervous system lymphoma, a rare type of brain cancer. Participants, who have not yet received treatment, are randomly assigned to r…

This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …

This study tests whether a drug called blinatumomab, given as a simple injection under the skin, can control small amounts of leftover leukemia cells (called measurable residual disease, or MRD) in adults with B-cell acute lymphoblastic leukemia. The goal is to prevent the cancer…

This trial tests whether a low-sodium diet can improve blood pressure control in people who had a hypertensive disorder of pregnancy. Participants receive either a provided diet with less than 2000 mg of sodium per day or a standard diet with no salt restrictions for the first we…

This trial explores whether transplanting gut bacteria from healthy donors can help restore the immune system in people who have weak immunity after a stem cell transplant. The study first observes immune recovery in patients to identify those with severe deficiency, then gives a…

This trial is testing whether a combination of pomalidomide (a pill) and rituximab (an infusion) can help young adults with high-risk diffuse large B-cell lymphoma (DLBCL) stay in remission after their first round of treatment. Participants, who must be under 60 and have responde…

This early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand si…

This phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior trea…

This study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy…

This phase III trial is testing whether an experimental drug called TQB3909 can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) whose disease has returned or stopped responding to prior treatments. Participants will be randomly assigned to re…

This phase 2 trial tests a drug called linvoseltamab in 34 people with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. Linvoseltamab is a bispecific antibody that helps the immune system attack myeloma cells. The main goal is to see how many patients respond…

This early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…

This early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…

This phase III trial is testing whether regular antibody infusions (immunoglobulin replacement therapy) can prevent infections better than standard antibiotic prophylaxis in people who have received CAR-T cell therapy for B-cell acute lymphoblastic leukemia or B-cell lymphoma. CA…

This phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…

This phase 2 trial is testing whether adding the targeted drug pirtobrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people newly diagnosed with a specific, harder-to-treat subtype of diffuse large B-cell lymphoma (Non-GCB DLBCL). The study will e…

This early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…

This trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…

This trial is testing whether adding pirtobrutinib, a targeted drug, to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific subtype of diffuse large B-cell lymphoma (non-GCB DLBCL). The study will enroll about 34 adults with newly diagnosed di…

This early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with …

This phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chanc…

This phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocyt…

This phase 2 trial is testing the drug glofitamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Glofitamab is a type of immunotherapy that helps the body's T-cells attack cancer cells. The study uses tumor biopsies tak…

This study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…

This trial tests whether adding an experimental drug called birelentinib to standard chemotherapy (R-CHOP) improves outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Participants receive either birelentinib plus R-CHOP or a placebo plus R-CHOP. The s…

This trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…

This phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…

This phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 …

This phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet…

This large clinical trial is testing whether adding the drug daratumumab to standard chemotherapy helps children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab is an antibody that targets a pr…

This phase 1 trial tests a new cell therapy called KITE-753 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. KITE-753 is made from a patient's own immune cells, which are modified to recognize and attack leuke…

This trial tests whether a combination of isatuximab plus a reduced-intensity version of standard chemotherapy (VRDlite) can effectively treat newly diagnosed multiple myeloma in frail older adults who are not candidates for a stem cell transplant. The study focuses on patients w…

This Phase 2 trial tests lisaftoclax, an oral drug that blocks a protein helping cancer cells survive. It enrolls 75 adults with certain slow-growing lymphomas (CLL, WM, or MZL) who either cannot take standard BTK inhibitors due to health issues or have stopped them due to side e…

This phase 2 trial is testing whether combining venetoclax and zanubrutinib can drive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into deep remission. The study enrolls adults who either have not been treated before or whose cancer returned at least two…

This phase II trial is testing whether combining two lab-made antibodies, tafasitamab and rituximab, can help people with newly diagnosed follicular lymphoma achieve complete remission. Both antibodies are designed to help the immune system recognize and attack cancer cells. The …

This early-phase trial tests whether giving the drug iberdomide before collecting a patient's T cells can improve the fitness of those cells for CAR-T therapy. The study enrolls adults with relapsed or refractory multiple myeloma who are already scheduled for standard CAR-T treat…

This phase 3 trial is testing whether an experimental drug called etentamig, combined with pomalidomide, can control multiple myeloma that has come back or stopped responding to treatment. About 520 adults who have already tried 1 to 3 prior therapies will be randomly assigned to…

This phase 2 trial is testing whether the experimental drug luvometinib, taken alone or with the chemotherapy drug cytarabine, can control Langerhans cell histiocytosis—a rare disease where immune cells build up and damage tissues. People aged 10 and older who need systemic treat…

This trial tests whether adding the bispecific antibody glofitamab to standard chemoimmunotherapy can improve outcomes for people with Burkitt lymphoma or high-grade B-cell lymphoma with MYC and BCL2 rearrangements. These are fast-growing cancers that can be hard to treat. The st…

This trial tests whether adding a small dose of total body radiation to standard CAR T-cell therapy can help the immune cells grow stronger and last longer in the body. It enrolls adults with relapsed or hard-to-treat diffuse large B-cell lymphoma or multiple myeloma who are alre…

This study tests an experimental drug called dibotatug (DR-01) in adults with bone marrow failure syndromes, including severe aplastic anemia. The goal is to see if the drug is safe and can improve blood cell counts. Participants receive dibotatug by IV infusion, and researchers …

This phase 3 trial is testing whether a new drug called BLB101 works as well as the approved drug Blincyto for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The study will compare how the drugs are …

This trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100…

This early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…

This phase 3 trial is testing whether a combination of three targeted drugs—orelabrutinib, obinutuzumab, and lenalidomide—can work as well as or better than standard chemotherapy for people with previously untreated follicular lymphoma. The goal is to see if this chemo-free appro…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

This study tests whether an artificial intelligence (AI) system can help choose the best combination of drugs for older patients newly diagnosed with large B-cell lymphoma. Participants are first treated with a standard two-drug regimen (ZR2), then those at intermediate or high r…

This early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy coc…

This study tests a combination of four drugs—sotoclax, carfilzomib, lenalidomide, and dexamethasone (called SonKRd)—in people newly diagnosed with multiple myeloma that has a specific genetic change called t(11;14). Participants must be healthy enough for a stem cell transplant. …

This phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …

This phase 2 trial tests an experimental biologic called MK-1045 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study aims to see if MK-1045 is safe and tolerable, and how many participants respond to treatment. P…

This study is for people with a slow-growing type of lymphoma called MALT lymphoma that has not spread. It compares a very low dose of radiation (4 Gy) combined with the targeted drug orelabrutinib against the standard higher dose of radiation (24 Gy). The goal is to see if the g…

This phase 1 trial tests an experimental therapy called 20-19 Tan BB06z CAR-T for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to treatment. The therapy involves taking a patient's own immune T cells, genetically modifying the…

This study tests a new treatment called CD70.CAR NK cells for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to or came back quickly after initial therapy. The treatment uses specially designed immune cells from a donor to find and attack cance…

This phase 2 study tests a chemotherapy-free combination of two targeted drugs—polatuzumab vedotin and glofitamab—in people with diffuse large B-cell lymphoma that did not respond to or returned within a year of initial R-CHOP therapy. The drugs work by directly killing cancer ce…

This phase II trial tests whether a drug called mosunetuzumab works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has returned or stopped responding to treatment. The study will enroll 138 participants and mea…

This clinical trial is testing whether adding an experimental drug called HDM2005 to a standard treatment (rituximab and lenalidomide) can help people with mantle cell lymphoma whose cancer has returned or not responded to previous therapies. The study involves about 40 adults an…

This study tests whether adding the immunotherapy drug glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than usual treatments for people with large B-cell lymphoma that has returned or not responded to first therapy. About 96 adults will be randomly …

This study looks at how well a drug called glofitamab (a bispecific antibody) works for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are observing about 200 adults in China who are already…

This phase 2 trial tests an investigational drug called YKST02 in adults with multiple myeloma that has relapsed or stopped responding to prior treatments. YKST02 is a bispecific antibody designed to bind both myeloma cells and immune T cells, potentially helping the immune syste…

This early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…

This study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells brea…

This phase 2 trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—as a first treatment for people with chronic lymphocytic leukemia (CLL). The goal is to see if this cocktail can reduce the disease to undetectable levels in the bone marrow and bloo…

This early-phase trial tests the safety and best dose of glofitamab, an antibody that helps the immune system attack cancer, when given alongside standard chemotherapy (R-CHOP and R-DHAP) for people with untreated mantle cell lymphoma. Sixteen adults aged 18 to 75 with stage II b…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This study tests a new drug called ABBV-383 in 38 people with Waldenström macroglobulinemia that has come back or not responded to treatment. The drug is a monoclonal antibody designed to block cancer growth. The trial has two parts: first finding a safe dose, then checking how w…

This study tracks people with severe eosinophilic asthma who already take Fasenra (benralizumab) every 8 weeks. Participants use electronic monitors on their regular inhalers and a study-provided rescue inhaler (AirSupra) to see if asthma control stays steady throughout the dosin…

This study tests a text- and web-based tool called FamilyCHESS, designed to help people with moderate to severe opioid use disorder begin and stay on medication. The tool also involves a concerned family member or friend who provides support. Researchers will compare outcomes lik…

This study tests two chemotherapy-free treatments for people newly diagnosed with AL amyloidosis, a rare blood disorder. The choice of treatment depends on whether the patient has a specific genetic change called t(11;14). Those with t(11;14) receive a daily pill called sonrotocl…

This phase 2 study tests whether combining two oral drugs — lisaftoclax and pirtobrutinib — can shrink or control mantle cell lymphoma in adults whose cancer has stopped responding to or caused intolerance to prior BTK-targeted treatments. Participants take both pills daily until…

This phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…

This study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or sto…

This phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…

This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, follow…

This 12-week study tests whether a weekly injection of tirzepatide, a drug used for diabetes, combined with motivational therapy can help adults with moderate to severe cannabis use disorder. Fifteen participants will receive escalating doses of tirzepatide along with counseling.…

This study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 pro…

This phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …

This phase 2 trial tests two oral drugs, nemtabrutinib and venetoclax, as a first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination can make cancer cells undetectable in the blood. About 25 adul…

This early-stage trial tests whether adding sonrotoclax to standard Pola-R-CHP chemotherapy can improve outcomes for people with untreated large B-cell lymphoma that has high BCL2 expression or double-hit features. The study has two parts: first, finding a safe dose of sonrotocla…

This trial tests whether adding low-dose total body irradiation (TBI) to standard chemotherapy before CAR T-cell therapy (tisagenlecleucel) is safe and effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. The study involves 18 pa…

This phase 2 trial is testing whether a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—can safely control chronic lymphocytic leukemia (CLL) in people who have not yet received treatment. About 40 participants will receive all three drugs orally. The main …

This study tests whether taking a daily antibiotic (levofloxacin) can safely reduce infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. The trial will randomly assign 75 participants to either lev…

This early-phase trial tests a new type of immune cell therapy called GoFast CD19 CAR T-cells in 9 adults with relapsed or refractory large B-cell lymphoma. Participants receive chemotherapy followed by an infusion of their own modified immune cells. The study aims to see if the …

This study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The go…

This Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …

This phase 2 trial compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or have deferred a stem cell transplant. One group gets the experimental drug elranatamab plus standard medications (lenalidomide, bortezomib, dexamethasone…

This study tests whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay on medication for opioid use disorder compared to referring them elsewhere. About 512 adults who use SSPs and have moderate to severe opioid use …

This study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…

This pilot study tests a new device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. Twenty adults with untreated mild hypertension will either get the real procedure or a sham (fake) one. The main goal is to see if the real t…

This phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…

This pilot study tests whether a connected blood pressure monitor, supervised daily by a healthcare assistant, helps patients with blood cancers like CLL or lymphoma stick to home monitoring. The goal is to catch and manage high blood pressure early, a common side effect of BTK i…

This study tests an experimental daily pill called HP-002 in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. It includes several ly…

This early-stage trial tests a new drug called GSK5926371 in about 49 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Researchers will also …

This phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…

This phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive ritu…

This study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections…

This phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…

This study tests whether a year-long lifestyle program (diet, exercise, and other healthy habits) can improve key blood markers in people with MGUS or smoldering myeloma—two early, often symptom-free conditions that can lead to multiple myeloma. About 67 adults will participate, …

This study tests a combination of two drugs, belantamab mafodotin and mezigdomide, in 44 adults with multiple myeloma whose cancer returned after treatment with CAR-T cells or bispecific antibodies. The goal is to see if the combo can control the cancer longer. The trial starts w…

This trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins on cancer cells at once. It is for adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after other treatments. The main goal is to find a s…

This study will follow 200 Chinese patients with relapsed or refractory B-cell acute lymphoblastic leukemia who receive a CAR-T cell therapy called puzolcabtagene autoleucel. The goal is to see how well it works in everyday medical practice, measuring response rates and how long …

This early-phase trial tests a new cell therapy called RN9101 in 19 adults with relapsed or refractory multiple myeloma, a blood cancer that has not responded to at least two prior treatments. RN9101 is a type of CAR-T cell therapy given as a single intravenous infusion. The main…

This study tests a new combination of drugs for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. About 46 participants will receive an experimental drug (EZH2 inhibitor) along with two other drugs (glofitamab and chemoth…

This phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…

This study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adu…

This study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments wil…

This early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …

This early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is…

This early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…

This phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming…

This study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …

This study tests a new medicine called Boya IVIG in 50 people with primary immunodeficiency (CVID or XLA), a condition where the body can't fight infections well. Participants get the drug every 21 or 28 days for a year to see if it keeps serious bacterial infections below one pe…

This Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…

This early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …

This Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…

This early-phase trial is testing a new treatment called PA3-17 injection for children and teens aged 3 to 18 with T-cell leukemia or lymphoma that has not responded to standard therapy or has come back. The treatment uses the patient's own immune cells, modified to recognize and…

This study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …

This study tests whether a compound from licorice root, called diammonium glycyrrhizinate, can reduce the toxic side effects and improve the cancer-killing power of CAR-T cell therapy in people with large B-cell lymphoma. About 21 participants will receive either standard care or…

This early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…

This Phase 2 trial tests whether adding the migraine drug rimegepant to a standard CAR-T cell therapy and another immunotherapy (glofitamab) can improve outcomes for people with high-risk relapsed or refractory large B-cell lymphoma. About 100 adults will be randomly assigned to …

This early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …

This early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. T…

This early-phase trial tests a new oral drug called golcadomide combined with standard chemotherapy drugs (pemetrexed, rituximab, and dexamethasone) in 18 adults with large B-cell lymphoma that has spread to the brain or central nervous system and has either returned or is not re…

This Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two y…

This study tests a new way to deliver radiation for gastric MALT lymphoma. Using AI, the treatment adapts each session to better protect nearby organs. About 25 adults with early-stage disease will take part. The goal is to see if this approach is safe and effective.

This study tests a personalized treatment approach for people with large B-cell lymphoma whose cancer did not respond to CAR-T cell therapy. Researchers will analyze the tumor's surrounding environment to classify it into one of four subtypes, then give patients a drug combinatio…

This study tests a new combination of three drugs (lisaftoclax, chidamide, and rituximab) in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe and effective dose and see if th…

This study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…

This study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …

This trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …

This study looks at two stem cell transplant methods—using a patient's own cells or a donor's cells—as a follow-up treatment for people with T-cell acute lymphoblastic leukemia or lymphoma who are in their first complete remission. The goal is to see which approach better prevent…

This early-phase trial tests a new CAR-T cell therapy called GI001 in 9 adults with relapsed or refractory B-cell lymphoma. Participants receive a single infusion of engineered immune cells designed to attack cancer. The main goals are to check safety and find the right dose, wit…

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink tumors and how safe they are. About 27 newly diagnosed …

This study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and thro…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This early-phase study tests the safety of a new immunotherapy that creates cancer-fighting cells inside the body for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The treatment targets two proteins (BCMA and GPRC5D) on cancer cells. Researcher…

This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This study tests whether using a blood test (MRD) after two cycles of chemoimmunotherapy can guide the use of low-dose radiation in patients with diffuse large B-cell lymphoma. Patients with detectable cancer DNA in their blood may receive targeted radiation to remaining spots on…

This Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…

This Phase 2 trial tests whether adding the drug nogapendekin alfa inbakicept (NAI) to standard sepsis care can improve survival in critically ill adults with sepsis and persistently low lymphocyte counts (a sign of immune suppression). About 50 participants will be randomly assi…

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and tafasitamab—in 35 people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this mix is safe and can lead to a complete response with very…

This early-stage trial tests a new drug, golcadomide, combined with rituximab for people with mantle cell lymphoma that has come back or stopped responding to treatment. The study aims to find the safest dose and see if the combination can shrink tumors. About 58 adults will take…

This study tests a new drug called TQB2934 in 260 people whose multiple myeloma has returned or stopped responding to treatment. Participants are randomly assigned to receive either TQB2934 or one of several standard treatments chosen by their doctor. The main goal is to see if T…

This early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to other treatments. RN1701 is a type of immune cell therapy made from donor cells, designed to target two markers on cancer cells. The study will enroll…

This early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors.…

This Phase 2 trial tests a CAR-T cell therapy called zamtocabtagene autoleucel as a first-line consolidation treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after standard chemotherapy. The main goal is to see how long they…

This study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…

This Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…

This early-phase study tests an experimental mRNA vaccine that targets the Epstein-Barr virus (EBV) in people with HIV who have lymphoma. The vaccine aims to help the immune system fight tumors linked to EBV. The study will enroll 6 adults and primarily check for safety and signs…

This study tests a new combination of drugs (mosunetuzumab and polatuzumab vedotin) plus chemotherapy for elderly patients (70 and older) with a newly diagnosed type of lymphoma called diffuse large B-cell lymphoma. The goal is to see if this approach helps more patients achieve …

This phase 2 trial tests a combination of seven drugs (CL-Pola-R-CHP) in 28 adults aged 65 and older with double or triple-hit diffuse large B-cell lymphoma who are not eligible for transplant. The goal is to see how many patients achieve complete remission after six cycles of tr…

This early-phase study tests a new type of CAR-T cell therapy that uses tiny antibodies (nanobodies) to target two markers on cancer cells (CD19 and CD20). The goal is to see if it is safe and to find the best dose for people with B-cell lymphoma that has come back or not respond…

This study tests a chemotherapy-free combination of three drugs (sonrotoclax, zanubrutinib, and rituximab) in 52 adults with previously untreated follicular lymphoma. The goal is to see if this approach can produce deeper and longer-lasting remissions while being easier to tolera…

This early-phase study tests whether a combination of three drugs (sonrotoclax, zanubrutinib, and obinutuzumab) can shrink or eliminate mantle cell lymphoma in people with high-risk forms of the disease. About 28 newly diagnosed adults will receive the treatment and be monitored …

This study tests whether adding thiotepa to the standard melphalan treatment before a stem cell transplant can lower the chance of multiple myeloma coming back within a year. It includes 204 adults aged 18-70 whose cancer was not fully cleared by prior therapy. Participants are r…

This phase II trial is testing the safety and effectiveness of combining two drugs, mosunetuzumab and pirtobrutinib, in 25 adults with relapsed or refractory Waldenstrom Macroglobulinemia, a rare blood cancer. Participants must have had at least one prior treatment. The study aim…

This phase 2 trial tests whether adding a drug called glofitamab before and after standard CAR-T cell therapy can improve outcomes for 20 adults with high-risk, relapsed or refractory large B-cell lymphoma. Participants first receive glofitamab with chemotherapy, then CAR-T cells…

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…

This early-phase study tests a new treatment called CY-219 CAR-T cells in 18 people whose B-cell lymphoma has come back or stopped responding to standard care. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are …

This early study tests a new type of immune cell therapy called Sup19 CAR-T in 9 adults with B-cell acute lymphoblastic leukemia or lymphoma. It is for patients whose cancer stopped responding to previous CD19-targeted treatments or has low levels of CD19. The main goal is to che…

This early-phase trial tests a new gene therapy called QI-019B for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy works by creating cancer-fighting CAR-T cells directly inside the patient's body. The study will enroll…

This early-stage trial tests a new drug called BR101 in 10 people with multiple myeloma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at whether the drug helps shrink the ca…

This phase 2 trial tests whether personalized drug combinations can help people with relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL). Researchers will assign patients to one of several targeted therapies based on lab tests. The main goal is to see if t…

This study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.

This study tests a new drug called NX-5948 (bexobrutideg) combined with other medicines (venetoclax, and possibly rituximab or obinutuzumab) in adults with B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. The goal is to see if the combination is safe …

This study tests a drug called pirtobrutinib in 40 people with mature B-cell lymphoma whose cancer has worsened or who cannot tolerate other BTK inhibitor drugs. Participants take one pill daily. Researchers will measure how many patients respond, how long the response lasts, and…

This study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…

This early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…

This study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receiv…

This study tests whether a new drug combination (C Pola R-CHP+X) works better than the standard treatment (CR-CHOP) for people with a fast-growing type of lymphoma called double-expressor diffuse large B-cell lymphoma. About 156 adults aged 18-75 who have not been treated before …

This phase 2 trial is testing two oral drugs, BGB-16673 and sonrotoclax, in 40 people with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can safely control the disease for a limited time, potentially reducing the need for ongoing therapy. Pa…

This early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…

This early study is testing a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard treatments. RN1701 is a type of immunotherapy made from donor cells (allogeneic CAR-T) that targets two proteins on cancer cells. The main goa…

This study tests whether adding zanubrutinib to the standard R2 regimen (rituximab and lenalidomide) improves outcomes for adults with newly diagnosed follicular lymphoma. About 100 participants will be randomly assigned to receive either the new ZR2 combo or standard R2, followe…

This trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…

This phase 2 trial is testing a combination of three drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first-line treatment for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. The goal is to see if this chemo-free approach can shrink tumors an…

This early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein call…

This early-stage trial tests a new 'universal' cell therapy (QH103) for people with a hard-to-treat type of leukemia (B-ALL) that has come back or not responded to standard treatment. The therapy uses donor immune cells engineered to target cancer cells, given after chemotherapy …

This study looks at three different drug combinations for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The goal is to see which combination works best to shrink tumors and keep the cancer from coming back, while also checking for side eff…

This early study tests a new treatment called DIT101 for people with blood cancers that have come back or stopped responding to other treatments. DIT101 is given as an IV infusion and works by creating cancer-fighting cells inside the body, avoiding the need to remove and modify …

This phase 2 trial tests whether giving daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can work as well as the standard schedule for multiple myeloma patients after a stem cell transplant. The goal is to reduce costs and clinic visits while ma…

This early-phase trial tests a single infusion of CD7 CAR-T cells in 10 children with high-risk T-cell acute lymphoblastic leukemia or lymphoma who have already achieved remission. The goal is to see if this immune cell therapy can safely eliminate remaining cancer cells and redu…

This study tests a new drug combination for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The treatment uses three immune-based drugs (CD19 t-haNK, NAI, and rituximab) without chemotherapy. About 20 adults …

This study tests a new treatment called SYS6055 for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses specially designed cells to target and attack cancer cells. The trial will check if it is safe, what dose works b…

This early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tu…

This phase 3 trial tests two immunotherapy drugs, inotuzumab and blinatumomab, in 750 children with relapsed B-cell acute lymphoblastic leukemia. The goal is to replace toxic chemotherapy with targeted, less harmful treatments to improve survival and reduce side effects. Particip…

This study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back after initial treatment. About 20 adults will take part, and their doctors will decide if they get glofitamab al…

This trial is for adults with multiple myeloma or Waldenstrom macroglobulinaemia. It tests whether giving certain drugs less often can control the disease as well as the standard schedule. The goal is to find the best balance between effectiveness and quality of life. About 400 p…

This study tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) in people with Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to see how well the treatment shrinks tumors and controls the disease. About 19 adults who have not yet been t…

This early-phase trial tests a personalized cell therapy called CART-BCMA in 3 Thai patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses the patient's own immune cells, modified in a lab to target and kill mye…

This study tests if a shot (subcutaneous) of the drug blinatumomab works as well as the standard IV drip for adults with a certain type of leukemia (Ph-negative B-cell ALL). About 560 people who are in remission after initial chemo will get either the shot or the IV, along with m…

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

This early-phase trial is testing a new type of immune cell therapy called CD19X CAR-T for people with large B-cell lymphoma that has come back or not responded to other treatments. Only 3 participants will receive the therapy after a short course of chemotherapy to prepare their…

This study tests a new treatment plan for adults up to 65 years old with a type of leukemia called Ph-negative ALL. The goal is to see if adding an immunotherapy drug called blinatumomab improves survival compared to the previous treatment plan. About 330 participants will receiv…

This study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…

This phase 2 trial tests whether giving two bispecific antibodies (teclistamab and talquetamab) in sequence, along with other drugs, can improve survival in 50 people with high-risk multiple myeloma. Some participants may also receive a stem cell transplant if cancer cells remain…

This study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…

This early-phase trial is testing a new drug called IBI3003 in about 360 people with multiple myeloma that has returned or no longer responds to standard treatments. The study has two parts: first, finding the safest and most effective dose, and then testing how well it works. Pa…

This study tests a new drug called EMB-07, which is a bispecific antibody that helps the immune system attack cancer cells. It is for people with aggressive B-cell non-Hodgkin lymphoma, either newly diagnosed or whose cancer has come back. The trial will check safety, side effect…

This early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 parti…

This study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, testing the s…

This phase 2 trial tests a combination of zanubrutinib (a targeted drug) plus chemotherapy for people newly diagnosed with central nervous system lymphoma. Nineteen participants will receive the treatment, with an extra drug for those with a specific gene mutation. The goal is to…

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma — a blood cancer that has stopped responding to standard treatments. Ten adults will receive the antibo…

This early-phase trial tests JY509, a universal natural killer (NK) cell therapy, in 18 children with relapsed or refractory B-cell acute lymphoblastic leukemia. The cells are given as a single injection to see if they are safe and can help control the disease. The study uses a d…

This early-phase trial tests a new cell therapy called SL4903 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better attack the cancer. The main goal is to check safety an…

This early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults…

This study tests whether adding the experimental drug lisatoclax to standard chemotherapy (R-CHOP or Pola-R-CHP) can safely improve outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 122 adults aged 18-70 will take part. The goal is to see if the comb…

This phase II trial will test two different drug combinations in 70 people whose diffuse large B-cell lymphoma has returned more than a year after initial treatment. One group gets a modified R-MINE regimen (rituximab, ifosfamide, mitoxantrone liposome, etoposide), the other gets…

This study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…

This phase 2 trial tests glofitamab, an antibody that helps immune cells attack lymphoma, in 40 adults with relapsed or refractory diffuse large B-cell lymphoma who are eligible for a stem cell transplant. Glofitamab is given before transplant as a 'bridge' to shrink the cancer, …

This early study tests a new CAR-T cell therapy that is made inside the body, avoiding the complex and costly lab process. It targets two proteins (CD19 and BAFF-R) on cancer cells in people with relapsed or hard-to-treat B-cell leukemia or lymphoma. The main goals are to check s…

This study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack two cancer targets. The goal is to see if it is saf…

This study tests an experimental antibody drug called A-319 for people with a type of leukemia (B-ALL) that has come back or not fully cleared after chemotherapy. The drug is given as a shot under the skin and aims to help the immune system attack cancer cells. The main goals are…

This Phase 3 trial tests whether adding the experimental drug IMM0306 to standard lenalidomide can improve outcomes for people with follicular lymphoma that has returned or stopped responding to treatment. About 198 participants will be randomly assigned to receive either IMM0306…

This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed…

This study compares a high-intensity loading dose of vitamin D2 to standard weekly dosing in 52 patients with newly diagnosed aggressive non-Hodgkin lymphoma who are also receiving standard chemotherapy. The goal is to see if the high-dose approach normalizes vitamin D levels fas…

This early-phase study tests a new treatment called QH103 for adults with B-cell lymphoma that has come back or not responded to standard therapy. QH103 uses specially engineered immune cells (CAR-γδT cells) from healthy donors to target and kill cancer cells. The main goals are …

This early-phase trial tests a new type of CAR-T therapy for B-cell blood cancers like lymphoma and leukemia. Instead of removing a patient's immune cells, modifying them in a lab, and infusing them back, this drug delivers genetic instructions directly into the body using tiny f…

This study tests whether a quick bedside ultrasound can help doctors decide if new mothers with preeclampsia need a diuretic (water pill) to lower their blood pressure. About 96 postpartum patients will be enrolled. The goal is to see if this approach speeds up blood pressure rec…

This early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to…

This pilot study will test whether a 12-week Korean-style Mediterranean diet, combined with daily step tracking, is feasible for people with MGUS or smoldering myeloma. Twenty adults will receive dietary counseling and a wearable device to monitor activity. Researchers will measu…

This early-phase trial tests a personalized treatment called IASO104 for people with relapsed or refractory multiple myeloma, a blood cancer that has not responded to standard therapies. IASO104 is made from a patient's own immune cells, which are genetically modified to recogniz…

This study tests a new treatment called TC011 for adults with follicular lymphoma that has come back or not responded to at least two prior therapies. TC011 is a type of CAR-T cell therapy that targets cancer cells. The main goal is to see how many patients' tumors shrink or disa…

This Phase 2 trial is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 70 adults with relapsed or refractory multiple myeloma. The goal is to see if this combo can slow or stop the cancer from growing. Participants must have already tried lenali…

This study tests a new treatment called AcNK-Sup003 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if it is safe and to find the best dose. About 28 adults will take part, and resear…

This study tests whether adding inhaled nitric oxide (iNO) to standard care helps adults with moderate-to-severe acute respiratory distress syndrome (ARDS) survive longer. About 536 participants will be randomly assigned to receive iNO or a placebo through their ventilator. The m…

This early-phase trial tests a new mRNA drug called WGb-0301 in 9 patients with B-cell cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. The drug uses lipid nanoparticles to deliver mRNA that targets a protein called CD19 on cancer cells.…

This early-stage study tests a personalized mRNA vaccine (XP-006) for people with B-cell non-Hodgkin's lymphoma that has returned or not responded to treatment. The vaccine is custom-made to target each person's tumor. The main goal is to check safety and find the right dose, whi…

This study compares a four-drug regimen (isatuximab plus standard VRD) against the standard three-drug VRD in 117 newly diagnosed multiple myeloma patients who are not eligible for transplant and have high-risk features. The goal is to see if adding isatuximab leads to more patie…

This early-phase trial tests a new type of CAR-T cell therapy (with a protein called TLR2) in 60 adults newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma who cannot tolerate intensive chemotherapy. Participants receive a single infusion of these engineered immu…

This study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk, hard-to-treat type of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive the combination and be monito…

This early-phase trial will test the safety of an experimental cell therapy called LV009 injection in 19 adults with relapsed or refractory CD19-positive blood cancers. Participants receive a single infusion, then are monitored for side effects and tumor response for up to 24 mon…

This early-phase trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with relapsed or refractory B-cell acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants receive a single infusion of these modif…

This early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard therapy. RN1701 uses specially engineered immune cells from a donor to target and kill cancer cells. The main goals are to check safety and s…

This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to standard therapies. IASO206 is a type of CAR-T therapy that uses a patient's own immune cells to attack cancer cells. The trial will enroll 12 adults…

This study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…

This early study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses donor immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check if it's safe, with a small…

This study tests a new drug called BEBT-908 combined with chemotherapy in adults with a rare, high-risk form of acute lymphoblastic leukemia (ALL) who are in remission but still have tiny amounts of cancer cells detectable. The goal is to see if the combo can clear those leftover…

This early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safe…

This study tests a combination of three drugs—zanubrutinib, rituximab, and lenalidomide—as the first treatment for people with marginal zone lymphoma that has spread or requires therapy. Researchers want to see if this drug mix helps tumors shrink or disappear and how safe it is.…

This early-stage study tests a new drug called QLS2313 in 124 adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants receive the …

This early-phase study tests a new type of immune therapy for people with certain blood cancers (leukemias) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells c…

This study tests a combination of three chemotherapy drugs (thiotepa, cyclophosphamide, and busulfan) given before a stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this approach helps keep the cancer from coming back. About 37 adults aged 18-70 who…

This early-phase study tests a personalized CAR-T cell therapy made at the bedside for adults with B-cell acute lymphoblastic leukemia. The treatment uses the patient's own immune cells to target and kill cancer cells. The main goals are to check safety, find the best dose, and s…

This early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This study tests a combination of targeted therapy (zanubrutinib) with a reduced-dose chemotherapy and an antibody drug for people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. About 43 participants will receive four cycles of the combo, then eight mont…

This study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults with mantle cell lymphoma that came back or didn't respond to BTK inhibitors. The goal is to improve remission rates and keep the cancer under control longer. Partic…

This early-stage trial is testing a new treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) using immune cells from donated umbilical cord blood that are engineered to attack cancer cells (UCAR-T). The study will enroll 50 participants to check safety, find the …

This study tests a combination of two oral drugs, zanubrutinib and BGB-11417, in adults with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combination can shrink or control the cancer better than current options. P…

This Phase 2 trial tests AD17002, a nasal spray that aims to calm the immune system in people with moderate to severe eosinophilic asthma that is not well controlled by current treatments. About 126 adults will receive either the spray or a placebo for 3 months. Researchers will …

This early study tests a new drug called STR-P004 in 11 adults with a type of leukemia (ALL) that has come back or not responded to standard treatments. The main goals are to check if the drug is safe, find the right dose, and see if it helps fight the cancer. Participants will r…

This Phase II trial is testing a combination of three drugs—glofitamab, polatuzumab vedotin, and zuberitamab—in 40 people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this chemo-free approach can achieve complete remission early in treatment. Particip…

This early-stage study is testing a new treatment called CT1195E CAR-T cells in 30 adults with B-cell blood cancers that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This phase 2 study tests pirtobrutinib, a daily oral drug, as a first treatment for elderly patients (70+) with mantle cell lymphoma who are considered unfit or frail. The goal is to see if the drug can control the cancer and delay progression. 56 participants will take the drug …

This study tests a new treatment for mantle cell lymphoma, a rare blood cancer. It combines chemotherapy with targeted drugs to see if it can keep the cancer from coming back. The study involves 45 people who have not been treated before, and uses scans and blood tests to guide t…

This study tests a new approach for primary central nervous system lymphoma (PCNSL), a rare brain cancer. It combines CAR-T cell therapy, a stem cell transplant, and two drugs (orelabrutinib and sintilimab) to see if the mix is safe and effective. The trial plans to enroll 30 adu…

This study tests whether taking zanubrutinib (a targeted cancer pill) for two years after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults whose cancer responded to CAR-T will receive the drug. The main goal is to see how many remain …

This early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will a…

This study tests whether adding brentuximab vedotin to standard chemotherapy (R-CHP) works better for people newly diagnosed with a rare, aggressive lymphoma linked to the Epstein-Barr virus. About 25 adults will receive the combination and be followed for 2 years to see if the c…

This early-phase trial is testing an experimental drug called MS-553 in 12 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. The main goal is to check the drug's safety and find the right dose…

This study tests whether a minimally invasive heart valve repair procedure (TEER) plus standard medication can reduce hospital readmissions over two years in people with moderate mitral regurgitation that worsens with exertion. About 300 participants will be randomly assigned to …

This trial is testing whether adding a targeted drug called orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma, a rare type of brain cancer. About 215 participants will be randomly assigned to one of…

This early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-labe…

This phase 2 trial tests a combination of three drugs (glofitamab, polatuzumab vedotin, and chemotherapy) in 80 adults with aggressive B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this cocktail can shrink tumors and improve survival. The…

This Phase 3 trial tests a new drug called TQB2825, a bispecific antibody that targets both CD3 and CD20 proteins, against standard immunotherapy for people with follicular lymphoma that has returned or not responded to treatment. About 228 participants will be randomly assigned …

This Phase 3 trial compares a new drug called CM336 against standard treatments for people with relapsed or refractory multiple myeloma who have already tried at least two prior therapies. About 280 participants will be randomly assigned to receive either CM336 or a standard-of-c…

This early-phase trial tests a new drug called BT02, a monoclonal antibody, in 116 adults with relapsed or refractory blood cancers like leukemia, lymphoma, or multiple myeloma. Participants receive the drug by IV every 2-3 weeks for up to two years. The main goals are to check s…

This early-phase trial will test a new type of immune cell therapy called bispecific AbTCR T-cells in 3 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, follicular, and Burkitt lymphoma). The cells are designed to target two proteins (CD19 and C…

This trial tests a combination of three drugs—capivasertib, venetoclax, and dexamethasone—in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study has two phases: first, to find the safest dose, and sec…

This study aims to personalize treatment for people newly diagnosed with multiple myeloma who have an extra copy of chromosome 1q, a marker of higher risk. Researchers will use a scoring system based on factors like disease stage and lab results to classify patients into low, int…

This early-phase trial tests a three-drug combination (ibrutinib, bendamustine, and rituximab) given for a fixed duration in people with Waldenström macroglobulinemia, a rare blood cancer. The study has two parts: first, finding the safest dose of bendamustine, and then testing t…

This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) in 62 adults with relapsed or refractory diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combo can shrink tumors. It's an early-phase t…

This early-stage trial tests a personalized cell therapy called CD19/22 CAR-T cells in 17 adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lymphoma. Patients receive their own immune cells that have been reprogrammed to target and kill cancer cells. The s…

This trial tests whether a new ultra-rapid genetic test, using third-generation sequencing, can diagnose familial lymphohistiocytosis (FHL) in children within 5 days instead of the usual 6-8 weeks. FHL is a rare, life-threatening genetic condition where the immune system attacks …

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study tests a new blood test that looks for DNA fragments in the blood (called cfDNA) to detect multiple myeloma and its early forms (MGUS and smoldering myeloma) in people over 40. The test uses machine learning to tell the difference between healthy individuals and those w…

This study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this me…

This study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…

This study tests a new type of PET/CT scan that uses a special tracer (68Ga-BCMA nanobody) to find multiple myeloma lesions in the body. Researchers will compare it to the standard FDG-PET/CT scan in 30 patients with newly diagnosed or relapsed multiple myeloma. The goal is to se…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it ta…

This trial tests whether giving patients a prescription for haloperidol to use as needed at home can help control symptoms of cannabinoid hyperemesis syndrome — a condition marked by severe nausea, vomiting, and abdominal pain from heavy cannabis use. The goal is to see if having…

This study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…

This study looks at whether people with multiple myeloma can safely give themselves the drug daratumumab at home instead of going to the hospital. About 50 patients will take turns receiving the injection at home and at the clinic to compare the two approaches. The goal is to see…

This study tests whether adding geriatric-guided care—including nutritional and physical therapy support—improves quality of life for elderly patients with diffuse large B-cell lymphoma. About 170 patients aged 70 and older who are unfit or frail will receive either this extra su…

This study tests whether medications that calm mast cells (ketotifen and cromolyn) can safely reduce persistent symptoms like fatigue, pain, and brain fog in people who had a tick-borne illness. Fifty adults aged 21-65 will receive either one of these drugs or a standard antihist…

This study tests whether taking a specific probiotic (Lactobacillus rhamnosus GG) with a special form of vitamin B2 for 12 weeks can improve memory and thinking in adults over 65 who have mild memory problems. Researchers will measure changes in cognitive tests and brain activity…

This study tests if taking fish oil by mouth can prevent or lessen nerve damage (peripheral neuropathy) caused by the chemotherapy drug bortezomib in people with multiple myeloma. Researchers will compare nerve health in 200 patients who take fish oil versus those who don't. The …

This study tests whether orthopedic check-ups and custom exercise plans can improve physical function and rehabilitation in people with multiple myeloma who have bone lesions. About 71 newly diagnosed patients will receive ongoing bone stability assessments and tailored exercise …

This study tests whether adding a controlled breathing program to a standard exercise routine improves heart and lung function in people with multiple myeloma. Twenty-six adults currently on treatment will take part in a 6-week program. One group will do breathing exercises at ho…

This study looks at whether adding a controlled breathing routine to a standard exercise program can reduce physical symptoms like pain and fatigue in adults with multiple myeloma. About 32 participants will take part in a 6-week program, with some doing extra breathing exercises…

This study looks at whether a special education program and a check-in on caregivers' own needs can boost the quality of life for people caring for someone with multiple myeloma. About 27 caregivers will take part. The goal is to see if this extra support helps them feel better a…

This study looks at whether a 12-week resistance exercise program can improve quality of life, reduce frailty, and boost mental health in people with multiple myeloma. Fifty patients will be split into two groups: one doing supervised exercise and the other doing the same exercis…

This observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adul…

This study aims to create 3D models of B-cell cancers—like chronic lymphocytic leukemia, splenic marginal-zone lymphoma, and hairy cell leukemia—using blood samples from patients. The goal is to build realistic models that mimic the tumor environment, which could help researchers…

This study aims to understand how symptoms of indolent systemic mastocytosis relate to biological signals in the body. Researchers will collect samples and data from 25 participants over 12 weeks to see how different treatments affect these signals. The goal is to improve underst…

This study investigates whether blocking a protein called IRAK4 can disrupt TLR signaling in leukemia cells from people with chronic lymphocytic leukemia (CLL). Researchers will collect extra blood samples from 50 adults with CLL during routine blood tests. In the lab, they will …

This study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely t…

This study looks at whether biologic therapy can reverse long-term lung damage in adults with severe asthma. Researchers will follow 150 patients and 50 healthy volunteers for two years, using advanced imaging and lung function tests. The goal is to see if treatment leads to 'cli…

This study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. T…

This study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…

This study aims to enroll 10,000 adults across the United States to help identify genetic variants linked to blood cancers such as leukemia, lymphoma, and myeloma. Participants complete online health surveys and provide a saliva sample by mail. Researchers will analyze the DNA to…

This study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…

This study investigates how often atrial fibrillation (AF), a type of irregular heartbeat, occurs in people with certain blood cancers who are starting a targeted cancer drug called a Bruton's tyrosine kinase inhibitor (BTKI). Researchers will follow 500 participants—400 starting…

This study explores whether self-administered digital cognitive tests can accurately measure thinking skills like attention, memory, and processing speed in people with primary central nervous system lymphoma or low-grade gliomas. Participants will complete both digital tests (on…

This study tests whether a blood test using mass spectrometry can detect minimal residual disease (tiny amounts of cancer left after treatment) in multiple myeloma patients. Currently, doctors must take bone marrow samples, which is painful and inconvenient. The blood test would …

This observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…

This study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…

This observational study will analyze tissue samples from 400 people with MALT lymphoma, a slow-growing cancer. Researchers aim to build a comprehensive molecular and cellular map of the disease across different body sites. The goal is to identify tumor subtypes and biomarkers th…

This study will follow 100 health science students for at least 10 years to understand why some people with very flexible joints (hypermobility) develop chronic pain, fatigue, and other health issues while others do not. Researchers will measure balance, heart rate, and quality o…

This study examines tumor samples from 100 people diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), a rare cancer that starts in the brain or spine. Researchers will use advanced genetic and molecular techniques to identify patterns in the …

This pilot study tests a new imaging method called PET-enabled dual-energy CT to measure bone and soft tissue in the bone marrow. It will include 45 adults: some with multiple myeloma scheduled for CAR T-cell therapy and some healthy volunteers. The goal is to see if this new met…

This study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …

This study collects blood and bone marrow samples from 80 people with B-cell non-Hodgkin lymphoma to explore why some cancers resist chemotherapy. Researchers will analyze the tumor and its environment, and develop lab models to test new treatments. The goal is to uncover resista…

This study looks at why some people with blood cancers like multiple myeloma or lymphoma choose not to receive treatment at home, or are not eligible for it. Researchers will interview patients, their caregivers, and healthcare staff, and review medical records and questionnaires…

This observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to unders…

This study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are receiving bispecific antibody therapy. Researchers want to understand why some patients don't respond or develop serious side effects. They will look at tumor samples, gut bacteria, a…

This early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and saf…

This Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…

This study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…

This study will follow 225 blood cancer patients receiving CAR-T therapy, bispecific antibodies, or high-dose chemotherapy with stem cell transplant. Researchers will test memory, attention, and thinking skills before treatment and up to 3 years after. The goal is to understand h…

This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver i…

This study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…

This study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…

This study surveys primary care doctors and nurse specialists in the West Midlands to understand how they decide to refer patients with chronic lymphocytic leukemia (CLL) to specialists. The goal is to identify differences in referral practices and find ways to make care more equ…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …

This study looks at two immune-related proteins, CD274 and CD276, in people newly diagnosed with B-cell cancers like leukemia and lymphoma. Researchers will use a blood test to measure these proteins and see how they help cancer hide from the immune system. The goal is to find be…

This study will measure two immune proteins, IL-17A and IL-10, in the blood of 80 people newly diagnosed with B-cell acute lymphoblastic leukemia. Researchers want to see if these levels are linked to lab results and how well patients respond to treatment. The goal is to learn mo…

This study will measure two immune system markers, CD305 and CD85d, on cancer cells from 180 people newly diagnosed with B-cell blood cancers. The goal is to see how these markers relate to different cancer types and patient outcomes. No treatment is given; the study only observe…

This study looks at whether the bacteria living in your gut can influence how well a drug called glofitamab works against diffuse large B-cell lymphoma (DLBCL). Researchers will collect stool samples from 30 patients before and after treatment to track changes in gut microbiome a…

This study will check if old tissue samples from 15 patients with extramedullary multiple myeloma can be used to find new biomarkers. Researchers will look at the samples and medical records to see if they are good enough for future research. No new treatments or tests are given—…

This study will check if stored tissue samples from 20 people with a specific type of multiple myeloma (t(4-14)) can be used to find new biomarkers. No new treatments or tests are given. The goal is to see if the samples are good enough for research.

This study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …

This study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …

This study tests whether giving less therapeutic food and requiring fewer clinic visits can still effectively treat severe acute malnutrition in children aged 6-59 months in Kenya. About 2,274 children will take part across 45 health facilities. The goal is to find a treatment ap…

This study looks at 50 adults with primary central nervous system lymphoma who are receiving high-dose methotrexate, a key chemotherapy. The goal is to see if measuring the drug early in the blood can predict later kidney problems. By identifying at-risk patients sooner, doctors …

This Phase 1 trial tests QL2109, a biosimilar to the multiple myeloma drug Darzalex, in 102 healthy Chinese men. The goal is to see if the body processes QL2109 similarly to Darzalex and to check for side effects. It does not test the drug's ability to treat cancer.

This study follows 65 patients getting stem cell transplants for blood cancers to see how their immune systems rebuild. Researchers will track B cells and antibody responses to vaccines before and after transplant. The goal is to improve vaccination schedules and infection protec…

This study will check if certain blood cell markers, called reticulocytes, can serve as early signs of bone marrow activity in people with chronic B lymphoproliferative neoplasms, a type of blood cancer. Researchers will measure reticulocyte counts and maturity levels in 120 newl…

This study looks at what happens to people with diffuse large B-cell lymphoma (a common blood cancer) after treatment with polatuzumab vedotin stops working. Researchers will track 200 patients in China to see which salvage treatments are used and how well they work. The goal is …

This early study tests a new PET imaging agent called 68Ga-NOTA-BCMA to see if it can safely and accurately show where anti-BCMA CAR-T cells go in the body and how long they last. Ten adults with multiple myeloma who are scheduled for CAR-T therapy will receive the tracer and und…

This observational study follows 162 patients with blood cancers who are receiving either a stem cell transplant or CAR-T therapy. Researchers will use a questionnaire to measure how symptoms and quality of life change from the start of hospital stay to discharge. The goal is to …

This study looks at medical records of 15,000 adults with chronic B-cell cancers to compare the risk of developing atrial fibrillation (an irregular heartbeat) between two drugs, zanubrutinib and acalabrutinib. Researchers will analyze data from a health database to see which dru…

This study looks at how a personalized strength training program affects people with different cancers, including lung, colon, breast, and blood cancers. 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers …

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study will follow 45 adults newly diagnosed with chronic lymphocytic leukemia (CLL) for at least one year. Researchers will collect blood samples and genetic information to see how certain markers, like IGHV mutations and chromosome changes, relate to how well patients respo…

This study will check for a mutation in the Notch1 gene in blood or bone marrow samples from 80 people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The goal is to see how common this mutation is and compare it between the two cancers. This is an observ…

This study will collect blood, saliva, urine, and stool samples from 500 adults with systemic histiocytosis—a group of rare inflammatory disorders. Researchers aim to identify biomarkers that could improve diagnosis, predict disease progression, and enable less invasive monitorin…